Peptide Science Info provides accurate, research-backed information on peptides, their mechanisms of action, and current scientific literature.
A review of retatrutide (LY3437943), Eli Lilly's investigational GIP, GLP-1, and glucagon receptor triple agonist, covering Phase II trial results, the rationale for triple agonism, and current Phase III development status.
A research review of semaglutide, the GLP-1 receptor agonist marketed as Ozempic and Wegovy, covering its structural design, FDA-approved indications, landmark clinical trial data, and safety profile.
A research review of tirzepatide (Mounjaro, Zepbound), the first FDA-approved dual GIP and GLP-1 receptor agonist, covering its mechanism, the SURPASS and SURMOUNT trial programs, and how dual agonism may differ from GLP-1 alone.
A practical framework for critically evaluating claims made about research peptides, including the questions to ask about any claim, how to spot common logical errors, and how to locate primary sources.
A framework for critically evaluating peptide research papers, including what to look for in methodology, statistical reporting, and the difference between in vitro and in vivo findings.
A review of the current scientific literature on BPC-157, a synthetic peptide derived from a gastric protein, including its studied mechanisms and research status.
The Glow Stack combines GHK-Cu, BPC-157, and TB-500—three peptides studied for skin regeneration, wound healing, and tissue repair. A review of the research on each component.
The KLOW Stack combines KPV, GHK-Cu, BPC-157, and TB-500—peptides studied for anti-inflammatory signaling, skin repair, wound healing, and connective tissue regeneration.
Tesamorelin is a synthetic GHRH analogue with FDA approval for HIV-associated lipodystrophy. Controlled trials show significant visceral fat reduction and IGF-1 elevation.
A review of retatrutide (LY3437943), Eli Lilly's investigational GIP, GLP-1, and glucagon receptor triple agonist, covering Phase II trial results, the rationale for triple agonism, and current Phase III development status.
A research review of semaglutide, the GLP-1 receptor agonist marketed as Ozempic and Wegovy, covering its structural design, FDA-approved indications, landmark clinical trial data, and safety profile.
A research review of tirzepatide (Mounjaro, Zepbound), the first FDA-approved dual GIP and GLP-1 receptor agonist, covering its mechanism, the SURPASS and SURMOUNT trial programs, and how dual agonism may differ from GLP-1 alone.
A practical framework for critically evaluating claims made about research peptides, including the questions to ask about any claim, how to spot common logical errors, and how to locate primary sources.
A framework for critically evaluating peptide research papers, including what to look for in methodology, statistical reporting, and the difference between in vitro and in vivo findings.
A review of the current scientific literature on BPC-157, a synthetic peptide derived from a gastric protein, including its studied mechanisms and research status.